Immunomodulatory Properties of Bone Marrow Mesenchymal Stem Cells from Patients with Amyotrophic Lateral Sclerosis and Healthy Donors
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68378041%3A_____%2F19%3A00508511" target="_blank" >RIV/68378041:_____/19:00508511 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11310/19:10409297
Result on the web
<a href="https://link.springer.com/article/10.1007%2Fs11481-018-9812-7" target="_blank" >https://link.springer.com/article/10.1007%2Fs11481-018-9812-7</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s11481-018-9812-7" target="_blank" >10.1007/s11481-018-9812-7</a>
Alternative languages
Result language
angličtina
Original language name
Immunomodulatory Properties of Bone Marrow Mesenchymal Stem Cells from Patients with Amyotrophic Lateral Sclerosis and Healthy Donors
Original language description
Pathogenesis of amyotrophic lateral sclerosis (ALS) involves several mechanisms resulting in a shift from a neuroprotective to a neurotoxic immune reaction. A promising tool for ALS treatment is represented by mesenchymal stem cells (MSCs), which possess both regenerative potential and immunomodulatory properties. In this study, we aimed to compare the immunomodulatory properties of MSCs isolated from the bone marrow of patients suffering from ALS and healthy donors. Moreover, the influence of proinflammatory cytokines on the immunoregulatory functions of MSCs was also evaluated. We found that MSCs from ALS patients and healthy donors comparably affected mitogen-stimulated peripheral blood mononuclear cells and reduced the percentage of T helper (Th)1, Th17 and CD8(+)CD25(+) lymphocytes. These MSCs also equally increased the percentage of Th2 and CD4(+)FOXP3(+) T lymphocytes. On the other hand, MSCs from ALS patients decreased more strongly the production of tumour necrosis factor-alpha than MSCs from healthy donors, but this difference was abrogated in the case of MSCs stimulated with cytokines. Significant differences between cytokine-treated MSCs from ALS patients and healthy donors were detected in the effects on the percentage of CD8(+)CD25(+) and CD4(+)FOXP3(+) T lymphocytes. In general, treatment of MSCs with cytokines results in a potentiation of their effects, but in the case of MSCs from ALS patients, it causes stagnation or even restriction of some of their immunomodulatory properties. We conclude that MSCs from ALS patients exert comparable immunomodulatory effects to MSCs from healthy donors, but respond differently to stimulation with proinflammatory cytokines.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30102 - Immunology
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Journal of Neuroimmune Pharmacology
ISSN
1557-1890
e-ISSN
—
Volume of the periodical
14
Issue of the periodical within the volume
2
Country of publishing house
US - UNITED STATES
Number of pages
11
Pages from-to
215-225
UT code for WoS article
000468351800005
EID of the result in the Scopus database
2-s2.0-85053686490